“showed a trend”

Akkermansia showed a trend toward higher abundance in the probiotic group (Δ probiotic = 0.0128, Δ control = 0.0034, p = 0.0829).

Time to complete healing also showed a trend towards efficacy ( p = 0.0829, Kaplan–Meier) with 0.1% RGN-259.

Furthermore, D1 mothers showed a trend to smaller liver weight compared to RD mothers ( P = 0.083) ( Fig. 2 a) but a reduction of more than a half in the total accumulated liver lipids compared to RD and D2 mothers ( P = 0.039 and P < 0.001, respectively) ( Fig. 2 b).

Univariate analysis showed a trend toward reduced VTE risk with reduced LMWH prophylaxis (OR = 0.31, 95% CI: 0.08–1.16, P = 0.083), which remained non-significant after multivariate adjustment for ALBI score, PT, cirrhosis, major hepatectomy, and other covariates (adjusted OR = 0.33, 95% CI: 0.09–1.21, P = 0.098).

HOMA-IR showed a trend towards a higher value in the group with complication, which did not reach statistical significance ( p = 0.083).

The three‐way 2 (Channel: F3, F4) × 2 (Type: A, S) × 6 (Order: ASAS, SASA, ASSA, SAAS, AASS, SSAA) repeated measures ANOVA on the power changes showed a trend toward a significant main effect of Type ( F (1,12) = 3.58, p < 0.083), and nonsignificant effects of Channel ( F (1,12) = 0.020, p < 0.889) and Order ( F (5,12) = 1.44, p < 0.280).

Tumor samples with Periostin high FAP low PDGFR low SMA high just showed a trend for a worse overall survival ( n (low) = 15, n (high) = 16, p = 0.083, Figure 2 B).

Early CA-AKI risk within 24 hours was notably influenced by clopidogrel (p<0.05), while ARBs showed a trend towards increased risk (p=0.083) and ticagrelor showed potential protection (p=0.076).

While the univariate analysis (Table 2 ) showed a trend toward a difference in the environmental domain at 12 months (early 75.2 [15.8] versus late 71.4 [15.2], p = 0.083), it was not statistically significant in the multivariate mixed model (Table 3 ; early 80.1 [95% CI: 73.9 to 86.2] versus late 74.7 [95% CI: 68.5 to 80.9], p = 0.209).

Median OS was 81.2 months; NSND showed a trend toward improved OS ( p = 0.083) and improved OS after age/sex adjustment (HR 0.64, 95% CI 0.42–0.98), but not after full clinicopathologic adjustment; DSS did not differ ( p = 0.59).

Result Compared to the NC group, SCD subjects showed a trend toward accelerated decline in executive function (Shape Trail Test (STT)‐A score, β= ‐0.04, p = 0.083).

WF-ORI imaging showed a trend towards an increase in ΔORR (i.e., treatment resistant) between control and FOLFOX-treated PDCOs ( p = 0.083; Figure 3 A).

In our cohort, female sex showed a trend toward association with worse OS (HR 1.49; 95% CI, 0.95–2.35; p = 0.083), although this did not reach statistical significance.

However, both the pCD and pUC groups showed a trend towards decreased richness ( p = 0.083 and 0.086, respectively; Fig. 2 A, B) and towards lower Shannon index values compared to controls ( p = 0.105 and 0.138, respectively; Fig. 2 A, B).

Age at diagnosis showed a trend toward statistical significance, with an estimated hazard ratio (HR) of 1.50 (95% CI: 0.95–2.38, p = 0.083), indicating a possible increase in mortality risk with advancing age.

There were no significant differences in VAS scores between the groups of patients with each stabilizer, although the group of patients with the DIAM system in place showed a trend ( p = 0.083) toward better results than the group of patients with the Wallis system in place.

However, surgery showed a trend to having a higher proportion of ≥ 50% volume reduction in microcystic lesions (82% vs 68%, p = 0.083), while sclerotherapy was more effective in mixed lesions (80% vs 72%, p = 0.120).

perfringens strains was positively correlated with the in vitro NetB titre (Pearson r = 0.92; p = 0.028) but showed a trend towards a negative correlation with the in vitro alpha toxin production (Spearman r = −0.90; p = 0.083) ( Figure 6 ).

The results showed a trend for a difference ( Z = −1.731, p = 0.083, Cohen's d = 0.504) in the SSRT between the HTA (316.75 ± 32.94 ms) and LTA (299.78 ± 34.45 ms) groups.

No significant associations were observed for the Married or Separated/Single groups, although the latter showed a trend toward better performance (RR = 0.86; 95% CI: 0.72 to 1.00, p = 0.083).

Participants with false‐negative results showed a trend toward lower CD4 nadir counts compared with true negatives (median 102 [IQR, 51–290] vs. 268 [139–394] cells/μL, p = .083), and they had a significantly higher number of HPV genotypes (median, 5.0 [IQR, 5.0–9.0] vs. 3.0 [IQR, 1.0–5.0], p = .002) (Table S1 , Supporting Information).

These analyses revealed that participants with higher PPVT scores (thus, bigger vocabulary size) were in general good at learning novel words (association test accuracy; F(1,43) = 4.48, p = .040, η p 2 = .094), and showed a trend for better free recall on Day8 compared to Day1 ( F(1,41) = 3.16 , p = .083, η p 2 = .072).

In addition, newborns treated with propranolol showed a trend toward a reduced progression to stage 2 (RR 0.855, 95% CI 0.715-1.021; p = 0.083) and to stage 3 without plus (RR 0.724, 95% CI 0.491-1.069; p = 0.104).

IC showed a trend of improving local control, and adding IC improved the rate of LRFS from 88.2% of patients in the CCRT alone group to 97.7% of patients in IC+CCRT group (p=0.083) in this study.

Moreover, among ICR patients, revascularization of non-IRA, compared to revascularization of the IRA alone, showed a trend toward reducing long-term MACCE (HR: 0.256; 95% CI: 0.055–1.194; p = 0.083).